How Should Clinicians Choose Among Biologic and Small-Molecule Therapies for IBD?

Start with disease, not the drug list

Therapy selection begins by defining what must be controlled. In Crohn's disease, inflammatory luminal disease, stricturing disease, penetrating disease and perianal disease are not equivalent therapeutic problems. In ulcerative colitis, extent, endoscopic severity, steroid dependence, hospitalization history and prior acute severe disease influence risk. A patient with high inflammatory burden and deep ulcers needs a strategy that can achieve rapid, durable control; a patient with lower-risk disease may reasonably prioritize safety or route convenience.

The 2025 ACG Crohn's guideline moved further away from obligatory step-up therapy. For moderate-to-severe disease, clinicians should not require failure of thiopurines or methotrexate before considering an advanced therapy. That shift matters because cumulative inflammatory damage is itself harmful.

Think in mechanisms and patient profiles

• Anti-TNF agents remain important, particularly when rapid systemic control is needed, when there is fistulizing or perianal Crohn's disease, or when extraintestinal inflammatory disease makes a systemic mechanism attractive.
• Vedolizumab offers gut-selective therapy and can be attractive when minimizing systemic immunosuppression is a high priority.
• Ustekinumab and selective IL-23 inhibitors offer effective cytokine-targeted strategies and are increasingly central to both Crohn's disease and UC treatment algorithms.
• JAK inhibitors and S1P modulators provide oral options in UC; their speed and convenience are attractive, but age, cardiovascular risk, thromboembolic risk, infection risk and other regulatory safety considerations must be weighed carefully.
• Previous advanced-therapy exposure changes expected efficacy. First-line response rates are generally better than outcomes after multiple mechanism failures, so early treatment choice deserves deliberate attention.

Safety is not a footnote

Before advanced therapy, screen for infections as appropriate, update vaccinations, review prior malignancy, skin-cancer risk, cardiovascular and thromboembolic risks, pregnancy plans and concomitant immunosuppression. Safety is patient-specific: the therapy with the cleanest average trial profile is not automatically the safest therapy for a particular person.

Reassess early and objectively

A therapy choice is provisional until response is demonstrated. Symptoms alone can mislead. Use clinical response together with biomarkers such as C-reactive protein and fecal calprotectin, and confirm endoscopic improvement or healing at an appropriate interval. Primary nonresponse should trigger a different decision from secondary loss of response: dose optimization, drug-level assessment for selected therapies, or a mechanism change may be appropriate depending on the scenario.

A practical clinical approach

1. Define disease phenotype, severity, complications and prognostic risk.
2. List prior therapies and classify each failure as intolerance, primary nonresponse or secondary loss of response.
3. Identify comorbidities and extraintestinal manifestations that favor or disfavor particular mechanisms.
4. Decide how much speed, systemic activity, convenience and pregnancy compatibility matter.
5. Discuss route, monitoring burden, cost/access and patient preference before prescribing.
6. Set objective response targets before starting and reassess within a defined time window.

Common errors to avoid

• Choosing by habit ('my favorite biologic') instead of phenotype and patient risk.
• Allowing payer step therapy to substitute for clinical reasoning without documenting why a preferred therapy is indicated.
• Calling symptoms alone 'treatment failure' without checking inflammation.
• Continuing corticosteroids while labeling disease as controlled.

What should trainees remember?

Advanced IBD therapy is a positioning problem: match mechanism to phenotype, patient risk and prior exposure, then test the decision against objective targets. Avoid both reflexive step-up therapy and reflexive use of the newest agent.

Free further reading from Dr. Alan B. R. Thomson

For broader pharmacologic context, see Dr. Thomson's Clinical Pharmacology and Guideline-Based Management in Gastroenterology. These provide the therapeutic framework; current drug positioning should be updated against 2025-2026 society guidance.

Frequently asked questions

Is there one preferred first-line biologic for all moderate-to-severe IBD?

No. Disease phenotype, prior exposure, comorbidities and patient priorities materially change the preferred option.

Should patients with moderate-to-severe Crohn's disease fail thiopurines first?

Current ACG guidance does not require failure of conventional immunomodulators before advanced therapy when advanced treatment is clinically appropriate.

When should drug levels be checked?

Therapeutic drug monitoring is most established for anti-TNF therapy, especially when secondary loss of response is suspected; the value is less uniform across other mechanisms.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024. ISBN 979-8323955770.

2. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015. ISBN 978-1515078623.

3. Lichtenstein GR, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Updated June 2025. American College of Gastroenterology.

4. Rubin DT, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Updated June 2025. American College of Gastroenterology.

5. Turner D, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease. Gastroenterology. 2021;160:1570-1583.